Discovering new ways to effectively target and treat cancer is one of the most pressing challenges for the pharmaceutical industry today. The field of immuno-oncology is currently predicted to reach a value totalling $25 billion annually by 2020. At this crucial time of growth and advancement, this congress offers invaluable insights into key technological and scientific innovations. Addressing the main challenges and opportunities in the industry, delegates will learn more about hot areas including the discovery of novel viral, antibody and cell-based therapies, clinical partnerships and approaches to combination therapies.
Advances in Immuno-oncology Congress 2016
Evaluation of immune checkpoint markers and immune function of tumor infiltrated lymphocytes in tumor microenvironment
Dr. Emily Park, Senior Director in R&D at Advanced Cell Diagnostics
May 13th, 9:30am